SB's Factive not approved
SmithKline Beecham has received a non-approval letter from the FDA for its antibiotic gemifloxacin mesylate (Factive). Although disappointed with the decision, the company says it still intends to pursue the product.
SmithKline Beecham has received a non-approval letter from the FDA for its antibiotic gemifloxacin mesylate (Factive). Although disappointed with the decision, the company says it still intends to pursue the product.